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 Abstract    
Modern methods of diagnosis and treatment allow for better survival outcomes and, more importantly, for higher 
curability of cancer. Female cancer survivors often need eﬀective advice concerning the choice of birth control 
methods. The majority of gynecologists are reluctant to propose anything other than barrier methods due to lack 
of information concerning safe use of more eﬀective contraceptives. The aim of the paper was to summarize 
indications and contraindications to diﬀerent methods of contraception available to cancer survivors in Poland. 
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 Streszczenie    
Nowoczesne metody diagnostyki i leczenia nowotworów pozwoliły na zwiększenie przeżywalności i co najważniejsze 
zwiększenie wyleczalności nowotworów. Kobiety które wygrały walkę z nowotworem często potrzebują skutecznej 
porady dotyczącej wyboru metody antykoncepcji. U tych pacjentek, większość ginekologów niechętnie proponuje 
metody inne niż barierowe ze względu na brak informacji dotyczących bezpieczeństwa zastosowania metod o 
wyższej skuteczności. Celem pracy było przybliżenie bezpieczeństwa i ocena skuteczności różnych metod 
antykoncepcji u pacjentek po leczeniu lub w trakcie leczenia onkologicznego.
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Introduction
M??er? me????s ?? ?ia???sis a?? ?rea?me?? all?w ??r ?e??er 
sur?i?al ?u???mes a??, m?re im??r?a??l?, ??r ?i??er ?ura?ili?? ?? 
?a??er ?1?? ?emale ?a??er sur?i??rs ???e? ?ee? e??e??i?e a??i?e 
????er?i?? ??e ???i?e ?? ?ir?? ????r?l me????s? ??e ma??ri?? ?? 
???e??l??is?s are relu??a?? ?? ?r???se a????i?? ???er ??a? ?arrier 
methods due to lack of information concerning safe use of more 
effecti?e contrace?ti?es?
?e?ending on the stud?, from 1? to 2?? of ?oung female 
cancer sur?i?ors ha?e ?een re?orted to enter their meno?ause 
?rematurel?? ?n the other hand, it also means that as man? as ???
??? of the cured women can concei?e effecti?el? ?2??
?egardless of that, c?tostatic and?or radiation thera?ies are a 
direct indication to  contrace?tion also during the treatment, as it is 
highl? teratogenic ??? and it is not recommended for some female 
cancer sur?i?ors ?treated for e?g? ?reast cancer, choriocarcinoma? 
to concei?e for the ?eriod of e?en a few ?ears after their thera?? 
???? Moreo?er, a high num?er of ?oung women effecti?el? cured 
of cancer do not want to start a family for reasons other than 
their illness? ?t results in a high demand for effecti?e and safe 
contrace?ti?e methods for such ?atients?
?n account of ?ossi?le ad?erse effects of ?irth control, in 
?articular hormonal contrace?ti?es, it is ?ital to assess the o?arian 
reser?e of the female cancer sur?i?ors? ?ccording to the latest 
re?orts, the anti?M?llerian hormone ??M?? le?els, determined 
on the ???th day of the menstrual cycle, are the ?est ?redicti?e 
markers for such assessment ???, while the ?o?ular methods, 
such as ??? or estradiol le?el measurements or the antral follicle 
count, are not hel?ful in this res?ect?
?ontrace?ti?e methods currently registered and a?aila?le in 
?oland can ?e di?ided into ??e ty?es?
1. ?eha?ioral methods
2. Barrier methods
?. ?strogen and ?rogestin containing methods
?. ?rogestin?only methods 
?. ?ntrauterine de?ices ????s?
?ue to low effecti?eness of ?eha?ioral and ?arrier methods 
??earl inde? 1? and 2?, res?ecti?ely?, they are not recommended 
as the method of choice ???. ?mong ?irth control methods 
a?aila?le in ?oland, intrauterine de?ices, ?oth non?hormonal 
and le?onorgestrel?releasing ones, ha?e the highest effecti?eness 
determined with the ?earl inde?. Methods containing estrogens 
and ?rogestins or only ?rogestins ha?e slightly lower effecti?eness 
??earl inde? ? ?.???.??.
?ately it has ?een suggested that, on account of the 
?rolonged time of contrace?tion used ?y female cancer sur?i?ors, 
its effecti?eness should ?e assessed as a cumulated failure rate 
in a longer time unit, rather than, as to date, as a failure rate in a 
year of use. 
Highly effective reversible contraception
?? I??????????? ?????? ?IUD?
?he analysis of a ??e?year failure rate shows that the failure 
rate of intrauterine de?ices is ?.?? for the le?onorgestrel?releasing 
intrauterine de?ices and 1? for non?hormonal intrauterine 
de?ices ???.
?igh le?el of effecti?eness and full re?ersi?ility of this 
contrace?ti?e method, as well as the ?ossi?ility to ?erform all 
imaging scans ?including ?? and M???, makes it ?articularly 
a??lica?le to cancer ?atients and sur?i?ors, also those who ha?e 
ne?er gi?en ?irth ???. ?n addition, the coe?istence of cancer and 
other illnesses and risk factors ?e.g. throm?oem?olic disease, 
nicotinism, o?esity? increase the sco?e of a??lica?ility of the 
???s in com?arison to other methods of ?irth control.
?educed menstrual ?leeding is an additional ad?antage of 
the le?onorgestrel?releasing intrauterine de?ices. ?wing to that, 
?lood ?arameters do not worsen, which cannot ?e disregarded 
during cancer treatment.
?ow ?ercentage of infections u?on insertion of the ??? also 
allows for its a??lication in ?atients after immunosu??ressi?e 
thera?y. ?s shown in a study ?erformed ?y the ???, the 
?ercentage of intrauterine infections in such ?atients is com?ara?le 
to the grou? of ?atients not treated with immunosu??ressants ???.
?nother as?ect of the ???s is their a??lica?ility in 
hormone?de?endent ?reast cancer sur?i?ors. ?uring the use of 
le?onorgestrel?releasing intrauterine de?ices, detecta?le serum of 
le?onorgestrel was found in ?atient ?lood, which raised general 
concern o?er the a??lica?ility of this method ?1??. ?n their cohort 
study, ?rinh et al., ha?e not determined a higher num?er of ?reast 
cancer rela?ses in ?atients using the le?onorgestrel?releasing 
intrauterine de?ices ?11?. ?n a detailed analysis the in?estigators 
selected a grou? of ?atients who had already ?een using hormonal 
??? when they were diagnosed with ?reast cancer. ?he risk 
of rela?se in these ?atients turned out to ?e higher, although 
not statistically signi?cantly. ?es?ite a slightly higher risk of 
rela?se, the a??lication of le?onorgestrel?releasing ???s in 
?atients undergoing ?amo?ifen treatment constitutes a signi?cant 
?rotection factor against ?athological endometrial hy?er?lasia 
?12?. ?owe?er, the use of the hormonal ??? has not ?een ?ro?en 
to ?re?ent endometrial cancer in ?atients using ?ammo?ifen 
chronically ?1??.
?? ???? ???????? ???????????????
Mono?hasic, ?i?hasic and tri?hasic oral contrace?ti?es ???? 
ha?e ?een administered mainly to young women and nulli?arae. 
?owe?er, high effecti?eness of this contrace?ti?e method is 
accom?anied ?y many ad?erse effects and restricted a??lica?ility. 
?ts ad?antageous effects are mainly related to o?ulation 
su??ression mechanisms, antiandrogenic and anticancerogenic 
effects of many drugs ?1?, 1??.
?ormonal contrace?ti?es ha?e ?een ?ro?en to reduce the risk 
of o?arian cancer, endometrial cancer and colorectal cancer ?1??.
Most studies that can ?e referenced indicate a slight 
connection ?etween such contrace?ti?es and the de?elo?ment 
of hormone?de?endent ?reast cancer and its treatment. ? small 
num?er of studies re?ort an increased rate of ?reast cancer 
incidence ?1?, 1??.
?nlike ???s with le?onorgestrel, ??s used during the 
diagnostic ?rocess of malignant ?reast tumors do not affect the 
?rognosis or the course of disease ad?ersely ?1??. ?owe?er, there 
is no uni?ed ?iew?oint concerning the a??lica?ility of ??s in 
?atients after ?reast cancer treatment.
?ormonal contrace?ti?es are not recommended for front?line 
?atients diagnosed with hormone?de?endent cancer, including 
hormone?de?endent ?reast cancer ???. Moreo?er, drugs containing 
estrogens increase the already high risk of the throm?oem?olic 
disease for ?atients diagnosed with cancer ?2??.
©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n eNr 11/2013 957
  ginekologia 
? ? ? ? ? ? ? ? ? ? ? ? ? ? ?Ginekol Pol. 2013, 84, 955-958 
Jakub Rzepka, et al. Contraception for cancer survivors.
??????????????



































































































































©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e Nr 11/2013958
  ginekologia
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? Ginekol Pol. 2013, 84, 955-958 
Jakub Rzepka, et al. Contraception for cancer survivors.
?ormonal contrace?ti?es ha?e ?een shown to reduce the risk 
of o?arian cancer in the general ?o?ulation and in B??? mutation 
carriers ?22,2??. ? large study has demonstrated no correlation 
?etween ?reast cancer incidence in B??? mutation carriers 
using low?dose oral contrace?ti?es com?aring to non?carriers 
using the same drug ?2??. ?? use may e?en decrease the risk for 
early onset ?reast cancer in B??? 1 ?o?ulation. ?nfortunately, 
there are no data regarding the im?act of ?? formulations and the 
effect on cancer risk in B??? mutation carriers, although low?
dose ?? should ?e recommended to these women. ?? should not 
?e ?rescri?ed to ?reast cancer sur?i?ors with B??? mutations, to 
whom ?arrier methods or ??? de?ices can ?e ad?ised.
Emergency contraception
?omen choosing ?arrier and?or natural ?eha?ioral methods 
of ?irth control should ?e informed that they may use the so?
called emergency contrace?tion. ?n cases where there are 
a?solute contraindications to hormonal contrace?tion, it is worth 
considering the ??? insertion. ?he effecti?eness of this ?rocedure 
has ?een assessed as high and ?re?enting im?lantation u? to ? 
days after an un?rotected intercourse.
Conclusions
Birth control is a signi?cant factor that cannot ?e disregarded 
?y women after cancer treatment. ?he intrauterine de?ice is a 
highly relia?le, long?lasting, re?ersi?le and, most of all, chea? 
method for hormone?de?endent cancer sur?i?ors who would 
like an effecti?e contrace?tion method, while a le?onorgestrel?
releasing intrauterine de?ice is a recommended method for 
women undergoing ?amo?ifen treatment.
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